UNSPSC 51372106: Hydrocodone or dihydrocodeinone

This classification denotes an opioid receptor agonist and opioid and antitussive agent with the molecular formula C18H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6YKS4Y3WQ7, chemically known as 4,5-epoxy-3-methoxy-17-methylmorphinan-6-one but generally known as hydrocodone, which bears US NIH Compound Identifier 5284569. European Medicines Agency schedules Hydrocodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08063MIG. The term HYDROCODONE is an International Non-Proprietary Name.

UNSPSC 51372106 Hydrocodone or dihydrocodeinone is a Commodity code that describes controlled pharmaceutical substances, but recent state and local procurement activity tagged under this code does not match its nominal scope. The single recent opportunity in the dataset—Seminole County, Florida's IFB 60459723LAS—solicits naloxone and drug deactivation systems, which are opioid antagonists and harm-reduction equipment, not hydrocodone itself. This mismatch suggests either a data-entry error in the opportunity's code assignment or a broader tagging practice where opioid-related procurements are grouped under a single code family regardless of the specific pharmaceutical or device type. State and local health departments and county public-health agencies appear to be the primary issuing bodies using this code space, focused on community health and addiction-response initiatives rather than clinical pharmaceutical supply.

Seminole County, Florida posted the sole recent opportunity on June 30, 2026, with a response deadline of July 26, 2023 (noting a date inconsistency in the source). The county seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The IFB requires electronic bid submission through the county's e-Procurement Portal, unit pricing for each line item, drug-free workplace certification, E-Verify compliance, and standard insurance coverages. The contract carries a two-year initial term with one-year renewal option and includes FEMA funding with accompanying federal compliance requirements. Given the limited recent activity and the code-scope mismatch in available data, this code shows sparse current procurement momentum; firms pursuing state and local health-agency supply relationships should monitor for future opportunities rather than expect a steady stream of hydrocodone-specific solicitations at the state and local level.